2019
Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
Bhattarai S, Klimov S, Mittal K, Krishnamurti U, Li X, Oprea-Ilies G, Wetherilt C, Riaz A, Aleskandarany M, Green A, Ellis I, Cantuaria G, Gupta M, Manne U, Agboola J, Baskovich B, Janssen E, Callagy G, Walsh E, Mehta A, Dogra A, Shet T, Gajaria P, Traina T, Nggada H, Omonisi A, Ahmed S, Rakha E, Rida P, Aneja R. Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study. Cancers 2019, 11: 995. PMID: 31319547, PMCID: PMC6678933, DOI: 10.3390/cancers11070995.Peer-Reviewed Original ResearchTriple-negative breast cancerAR-positive triple-negative breast cancerAndrogen receptorAR statusPrognostic roleOverall survivalBetter prognosisBreast cancerAR-positive nucleiPatients' overall survivalReliable prognostic markersNegative breast cancerPotential therapeutic targetMulti-institutional studyAR positivityTNBC patientsPoor prognosisPrognostic valuePrimary tumorPatient prognosisIndian cohortPrognostic markerUK cohortAR antibodyTNBC samples
2017
HER3-EGFR score to predict clinical outcomes in triple-negative breast cancer.
Ogden A, Bhattarai S, Green A, Aleskandarany M, Rakha E, Ellis I, Li X, Krishnamurti U, Janssen E, Jonsdottir K, Reid M, Rida P, Aneja R. HER3-EGFR score to predict clinical outcomes in triple-negative breast cancer. Journal Of Clinical Oncology 2017, 35: 11612-11612. DOI: 10.1200/jco.2017.35.15_suppl.11612.Peer-Reviewed Original ResearchTNBC patientsDistant metastasisPrognostic valueBreast cancerCox proportional hazards regressionTriple-negative breast cancerProportional hazards regressionHigher immunohistochemical expressionTop upstream regulatorsMulti-institutional studyMann-Whitney U testCanonical pathwaysTop canonical pathwaysErbB family membersHER3 levelsPreclinical evidenceClinical outcomesHazards regressionHepatic fibrosisImmunohistochemical biomarkersImmunohistochemical expressionLuminal cytokeratinsMultivariable modelEGFR levelsFibrotic processNew Developments in Breast Cancer and Their Impact on Daily Practice in Pathology
Li X, Oprea-Ilies G, Krishnamurti U. New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology. Archives Of Pathology & Laboratory Medicine 2017, 141: 490-498. PMID: 28353377, DOI: 10.5858/arpa.2016-0288-sa.Peer-Reviewed Original ResearchConceptsBreast cancerDaily practiceBreast specimensTriple-negative breast cancerDistinct biological subsetsHER2/neu gene amplificationTumor-infiltrating lymphocytesRadioactive seed localizationAppropriate treatment groupsNovel clinical practicesNeu gene amplificationNeoadjuvant treatmentPathologic evaluationHistopathologic parametersTreatment groupsClinical practiceTherapeutic utilityBiological subsetsCancerMolecular classificationBest treatmentPathologyNew guidelinesSeed localizationGene amplificationMulti-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer
Ogden A, Garlapati C, Li X, Turaga R, Oprea-Ilies G, Wright N, Bhattarai S, Mittal K, Wetherilt C, Krishnamurti U, Reid M, Jones M, Gupta M, Osan R, Pattni S, Riaz A, Klimov S, Rao A, Cantuaria G, Rida P, Aneja R. Multi-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer. Scientific Reports 2017, 7: 42289. PMID: 28218233, PMCID: PMC5316996, DOI: 10.1038/srep42289.Peer-Reviewed Original ResearchConceptsDistant metastasis-free survivalProgression-free survivalTNBC cellsOverall survivalPoor prognosisBreast cancerTriple-negative breast cancer patientsTriple-negative breast cancerMultivariable Cox modelMetastasis-free survivalWorse overall survivalBreast cancer patientsMulti-institutional studyAA TNBC patientsAfrican AmericansAfrican American womenTNBC patientsIndependent biomarkerPrognostic valueCancer patientsWorse outcomesCox modelTissue microarrayKIFC1 knockdownTNBCTumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor–positive breast cancers
Krishnamurti U, Wetherilt C, Yang J, Peng L, Li X. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor–positive breast cancers. Human Pathology 2017, 64: 7-12. PMID: 28153508, DOI: 10.1016/j.humpath.2017.01.004.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBiopsyBreast NeoplasmsChemotherapy, AdjuvantDisease ProgressionDisease-Free SurvivalFemaleHumansLogistic ModelsLymphatic MetastasisLymphocytes, Tumor-InfiltratingMastectomyMultivariate AnalysisNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPredictive Value of TestsProportional Hazards ModelsReceptors, EstrogenRisk FactorsTime FactorsTreatment OutcomeTriple Negative Breast NeoplasmsConceptsTriple-negative breast cancerTumor-infiltrating lymphocytesDisease-free survivalBetter overall survivalLymph node statusOverall survivalBreast cancerNeoadjuvant treatmentLymphovascular invasionEstrogen receptor-positive breast cancerReceptor-positive breast cancerOncotype DX recurrence scoreOncotype DX scorePossible prognostic valueDX recurrence scoreNottingham histologic gradeNeoadjuvant settingTILs correlateNegative associationNode statusPrognostic valueRecurrence scoreHistologic gradePrognostic parametersPathological response
2016
Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer
Li X, Wetherilt C, Krishnamurti U, Yang J, Ma Y, Styblo T, Meisel J, Peng L, Siddiqui M, Cohen C, Aneja R. Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer. American Journal Of Clinical Pathology 2016, 146: 496-502. PMID: 27686176, DOI: 10.1093/ajcp/aqw134.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBetter disease-free survivalDisease-free survivalPD-L1 expressionPD-L1 stainingTumor-infiltrating lymphocytesStromal PD-L1 expressionPD-1 stainingLymphovascular invasionOverall survivalBreast cancerH-scoreTNBC casesTumor sizeCell death protein 1PD-1 expressionLymph node statusDeath protein 1Worse overall survivalKi-67 scoreFull-face sectionsNottingham histologic gradeNeoadjuvant therapyPD-1Node statusA multi-institutional study of racial differences in androgen receptor status among triple-negative breast cancers.
Bhattarai S, Xia J, Sonmez Wetherilt C, Pattni S, Klimov S, Riaz A, Aleskandarany M, Green A, Rakha E, Ellis I, Cantuaria G, Li X, Krishnamurti U, Osan R, Rida P, Aneja R. A multi-institutional study of racial differences in androgen receptor status among triple-negative breast cancers. Journal Of Clinical Oncology 2016, 34: 1089-1089. DOI: 10.1200/jco.2016.34.15_suppl.1089.Peer-Reviewed Original ResearchTriple-negative breast cancerAndrogen receptor statusMulti-institutional studyReceptor statusBreast cancerRacial differencesCancer